Performance of the insulin-only ilet bionic pancreas and the bihormonal ilet using dasiglucagon in adults with type 1 diabetes in a home-use setting

TY - JOUR

T1 - Performance of the insulin-only ilet bionic pancreas and the bihormonal ilet using dasiglucagon in adults with type 1 diabetes in a home-use setting

AU - Castellanos, Luz E.

AU - Balliro, Courtney A.

AU - Sherwood, Jordan S.

AU - Jafri, Rabab

AU - Hillard, Mallory A.

AU - Greaux, Evelyn

AU - Selagamsetty, Rajendranath

AU - Zheng, Hui

AU - El-Khatib, Firas H.

AU - Damiano, Edward R.

AU - Russell, Steven J.

N1 - Funding Information: Acknowledgments. The authors thank the participants for their time and effort; the diabetes care providers who referred potential participants to the study staff; the Massachusetts General Hospital (MGH) Diabetes Research Center study staff, Mary Larkin, Camille Staco-Targete, Nancy Kingori, Stephanie Dimodica, Khadija Tlaiti, and the Diabetes Research Center, MGH, for organizational and logistical support; Michele Sullivan for participating in the conduct of the trial; Camille Powe, Kerry Grennan, and Takara Stanley (MGH Pediatric Endocrine Division) for serving on the data safety and monitoring board for the study; and the members of the Partners Human Research Committee. Funding. L.E.C. received funding from National Institute of Diabetes and Digestive and Kidney Diseases grant 3R01-DK-119699-01S1. J.S.S. received funding from National Institute of Diabetes and Digestive and Kidney Diseases grant T32-DK-007028. Zealand Pharma donated the dasiglucagon for the study. This study was funded by Beta Bionics (Study 19-002). Duality of Interest. C.A.B. has received consulting fees from Beta Bionics and Novo Nordisk. E.R.D., F.H.E.-K., and R.S. are inventors on patents and patents pending related to the bionic pancreas technology. E.R.D. and F.H.E.-K. are employees, cofounders, and equity holders in Beta Bionics, Inc. E.R.D. is on the Board of Directors of Beta Bionics, Inc. R.S. is an employee in, and holds options to purchase stock in, Beta Bionics, Inc. S.J.R. is an inventor on a patent and patents pending on aspects of the bionic pancreas that are assigned to Massachusetts General Hospital and are licensed to Beta Bionics; has received honoraria and/or travel expenses for lectures from Novo Nordisk, Roche, and Ascensia; serves on the scientific advisory boards of Un-omedical and Companion Medical; has received consulting fees from Beta Bionics, Novo Nordisk, Senseonics, and Flexion Therapeutics; has received grant support from Zealand Pharma, Novo Nordisk, and Beta Bionics; and has received in-kind support in the form of technical support and/or donation of materials from Zealand Pharma, Ascencia, Sense-onics, Adocia, and Tandem Diabetes. No other potential conflicts of interest relevant to this article were reported. Author Contributions. L.E.C. and E.G. wrote the first draft of the letter. L.E.C., H.Z., and S.J.R. interpreted the data. C.A.B., J.S.S., R.J., M.A.H., E.G., R.S., F.H.E.-K., E.R.D., and S.J.R. participated in revision of the letter for important intellectual content. C.A.B., R.J., M.A.H., E.G., and S.J.R. enrolled and screened participants for the study and conducted study visits. C.A.B., F.H.E.-K., E.R.D., and S.J.R. designed the study. H.Z. performed the data analysis. F.H.E.-K. and E.R.D. designed the iLet. S.J.R. supervised the human studies. S.J.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PY - 2021

Y1 - 2021

UR - https://www.scopus.com/pages/publications/85111549752

UR - https://www.scopus.com/pages/publications/85111549752#tab=citedBy

U2 - 10.2337/dc20-1086

DO - 10.2337/dc20-1086

M3 - Letter

C2 - 33906916

AN - SCOPUS:85111549752

SN - 0149-5992

VL - 44

SP - e118-e120

JO - Diabetes care

JF - Diabetes care

IS - 6

ER -